Idexx Laboratories Inc /De (IDXX) — SEC Filings
Idexx Laboratories Inc /De (IDXX) — 35 SEC filings. Latest: 10-Q (May 5, 2026). Includes 19 8-K, 7 10-Q, 4 SC 13G/A.
View Idexx Laboratories Inc /De on SEC EDGAR
Overview
Idexx Laboratories Inc /De (IDXX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 26, 2026: IDEXX Laboratories Inc. filed an 8-K on March 26, 2026, reporting changes in its executive compensation structure under Item 5.02. This filing indicates that the company is updating how certain officers are compensated, which could impact future financial performance and executive retention. For inv
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 2 bullish, 33 neutral. The dominant filing sentiment for Idexx Laboratories Inc /De is neutral.
Filing Type Overview
Idexx Laboratories Inc /De (IDXX) has filed 7 10-Q, 19 8-K, 2 DEF 14A, 2 10-K, 4 SC 13G/A, 1 8-K/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (35)
Risk Profile
Risk Assessment: Of IDXX's 29 recent filings, 0 were flagged as high-risk, 5 as medium-risk, and 24 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1.105B |
| Net Income | $274.6M |
| EPS | $3.40 |
| Debt-to-Equity | 0.11 |
| Cash Position | $208.2M |
| Operating Margin | N/A |
| Total Assets | $3.387B |
| Total Debt | $829.8M |
Key Executives
- Roswell, Georgia
- Westbrook Maine
- Jonathan W. Ayers
- Michael J. Sweeney
- Dr. Sarah E. K. St. John
- Dr. Michael J. McGeary
Industry Context
IDEXX Laboratories operates in the global animal health diagnostics and software market. This sector is characterized by increasing pet ownership, rising demand for advanced veterinary care, and technological advancements in diagnostic tools. The industry is competitive, with a focus on innovation, product quality, and customer service to capture market share.
Top Tags
corporate-governance (6) · financial-reporting (6) · sec-filing (5) · 10-Q (4) · executive-compensation (3) · 8-k (3) · financial-condition (3) · Diagnostics (3) · financials (3) · diagnostics (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenue (Q3 2025) | $1.105B | Increased 13.3% from $975.5 million in Q3 2024 |
| Net Income (Q3 2025) | $274.6M | Increased 17.9% from $232.8 million in Q3 2024 |
| Diluted EPS (Q3 2025) | $3.40 | Increased from $2.80 in Q3 2024 |
| Total Revenue (YTD Sep 2025) | $3.213B | Increased 9.2% from $2.943 billion in YTD Sep 2024 |
| Net Income (YTD Sep 2025) | $811.3M | Increased 20.8% from $671.7 million in YTD Sep 2024 |
| Diluted EPS (YTD Sep 2025) | $9.99 | Increased from $8.05 in YTD Sep 2024 |
| Repurchases of Common Stock (YTD Sep 2025) | $979.2M | Significant cash outflow for share buybacks |
| Cash and Cash Equivalents (Sep 30, 2025) | $208.2M | Decreased from $288.3 million at Dec 31, 2024 |
| Research and Development Expenses (YTD Sep 2025) | $184.4M | Increased from $162.1 million in YTD Sep 2024 |
| Common Stock Shares Outstanding (Oct 29, 2025) | 79,851,330 | Reflects impact of share repurchases |
| Q2 2025 Total Revenue | $940.5M | Increased from $850.0M in Q2 2024, showing 10.6% growth. |
| Q2 2025 Net Income | $185.0M | Up from $160.0M in Q2 2024, indicating strong profitability. |
| Q2 2025 Product Revenue | $800.0M | Grew from $720.0M in Q2 2024, highlighting strong product sales. |
| Q2 2025 Service Revenue | $140.5M | Increased from $130.0M in Q2 2024, reflecting growth in service offerings. |
| H1 2025 Total Revenue | $1,850.0M | Higher than $1,680.0M in H1 2024, demonstrating sustained half-year growth. |
Forward-Looking Statements
- {"claim":"Vanguard will maintain a significant, passive stake in IDEXX Laboratories Inc. for the foreseeable future.","entity":"The Vanguard Group","targetDate":"December 2024","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Idexx Laboratories Inc /De (IDXX)?
Idexx Laboratories Inc /De has 35 recent SEC filings from Jan 2024 to May 2026, including 19 8-K, 7 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of IDXX filings?
Across 35 filings, the sentiment breakdown is: 2 bullish, 33 neutral. The dominant sentiment is neutral.
Where can I find Idexx Laboratories Inc /De SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Idexx Laboratories Inc /De (IDXX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Idexx Laboratories Inc /De?
Key financial highlights from Idexx Laboratories Inc /De's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for IDXX?
The investment thesis for IDXX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Idexx Laboratories Inc /De?
Key executives identified across Idexx Laboratories Inc /De's filings include Roswell, Georgia, Westbrook Maine, Jonathan W. Ayers, Michael J. Sweeney, Dr. Sarah E. K. St. John and 1 others.
What are the main risk factors for Idexx Laboratories Inc /De stock?
Of IDXX's 29 assessed filings, 0 were flagged high-risk, 5 medium-risk, and 24 low-risk.
What are recent predictions and forward guidance from Idexx Laboratories Inc /De?
Recent forward-looking statements from Idexx Laboratories Inc /De include guidance on {"claim":"Vanguard will maintain a significant, passive stake in IDEXX Laboratories Inc. for the foreseeable future.","e.